Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Tamás Schneider, András Rosta, Hajna Losonczy, Gáspár Radványi, György Ujj, Miklós Egyed, A. Illés, János Jakucs, László Szerafin, Zoltán Gasztonyi, T. Masszi, János Iványi, J. Demeter, Péter Dombi, Antal Tóth, Zita Borbényi

Research output: Article

2 Citations (Scopus)

Abstract

Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study. HUSOM was a phase III open-label, single-arm, multi-centre study aimed to assess the efficacy and the safety of the 12 cycles of rituximab (375 mg/m2 every 8 weeks) maintenance therapy in patients had already presented partial or complete response to R-CVP or R-CHOP. Efficacy endpoints such as event-free survival and overall survival were estimated. Adverse events were recorded during the entire course of the study. A total number of 124 patients were enrolled by 15 Hungarian study sites. Out of these, 86 patients received 12 cycles of rituximab and 69 patients completed the 3-year follow-up phase as well. The probabilities of the event free survival and progression at 4.3 years were estimated to be 70.3% and 74.4%, respectively. The overall and the disease free survival at 4 years were estimated to be 90.7% and 87.9%, respectively. A total number of 85 adverse events were reported during the study out of which 5 AEs were considered to be related to the administration of rituximab. Analyses of the efficacy variables have revealed comparable results to those reported by controlled clinical trials (EORTC 20981, PRIMA) conducted in parallel with the HUSOM study.

Original languageEnglish
Pages (from-to)199-205
Number of pages7
JournalPathology and Oncology Research
Volume24
Issue number2
DOIs
Publication statusPublished - ápr. 1 2018

Fingerprint

Follicular Lymphoma
Disease-Free Survival
Therapeutics
Survival
Controlled Clinical Trials
Rituximab
Safety
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study). / Schneider, Tamás; Rosta, András; Losonczy, Hajna; Radványi, Gáspár; Ujj, György; Egyed, Miklós; Illés, A.; Jakucs, János; Szerafin, László; Gasztonyi, Zoltán; Masszi, T.; Iványi, János; Demeter, J.; Dombi, Péter; Tóth, Antal; Borbényi, Zita.

In: Pathology and Oncology Research, Vol. 24, No. 2, 01.04.2018, p. 199-205.

Research output: Article

Schneider, Tamás ; Rosta, András ; Losonczy, Hajna ; Radványi, Gáspár ; Ujj, György ; Egyed, Miklós ; Illés, A. ; Jakucs, János ; Szerafin, László ; Gasztonyi, Zoltán ; Masszi, T. ; Iványi, János ; Demeter, J. ; Dombi, Péter ; Tóth, Antal ; Borbényi, Zita. / Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study). In: Pathology and Oncology Research. 2018 ; Vol. 24, No. 2. pp. 199-205.
@article{ddd23cc3d7f54c68809573c742aa69db,
title = "Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)",
abstract = "Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study. HUSOM was a phase III open-label, single-arm, multi-centre study aimed to assess the efficacy and the safety of the 12 cycles of rituximab (375 mg/m2 every 8 weeks) maintenance therapy in patients had already presented partial or complete response to R-CVP or R-CHOP. Efficacy endpoints such as event-free survival and overall survival were estimated. Adverse events were recorded during the entire course of the study. A total number of 124 patients were enrolled by 15 Hungarian study sites. Out of these, 86 patients received 12 cycles of rituximab and 69 patients completed the 3-year follow-up phase as well. The probabilities of the event free survival and progression at 4.3 years were estimated to be 70.3{\%} and 74.4{\%}, respectively. The overall and the disease free survival at 4 years were estimated to be 90.7{\%} and 87.9{\%}, respectively. A total number of 85 adverse events were reported during the study out of which 5 AEs were considered to be related to the administration of rituximab. Analyses of the efficacy variables have revealed comparable results to those reported by controlled clinical trials (EORTC 20981, PRIMA) conducted in parallel with the HUSOM study.",
keywords = "Drug safety, Event-free survival, Follicular lymphoma, Maintenance, Rituximab",
author = "Tam{\'a}s Schneider and Andr{\'a}s Rosta and Hajna Losonczy and G{\'a}sp{\'a}r Radv{\'a}nyi and Gy{\"o}rgy Ujj and Mikl{\'o}s Egyed and A. Ill{\'e}s and J{\'a}nos Jakucs and L{\'a}szl{\'o} Szerafin and Zolt{\'a}n Gasztonyi and T. Masszi and J{\'a}nos Iv{\'a}nyi and J. Demeter and P{\'e}ter Dombi and Antal T{\'o}th and Zita Borb{\'e}nyi",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s12253-017-0234-2",
language = "English",
volume = "24",
pages = "199--205",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

AU - Schneider, Tamás

AU - Rosta, András

AU - Losonczy, Hajna

AU - Radványi, Gáspár

AU - Ujj, György

AU - Egyed, Miklós

AU - Illés, A.

AU - Jakucs, János

AU - Szerafin, László

AU - Gasztonyi, Zoltán

AU - Masszi, T.

AU - Iványi, János

AU - Demeter, J.

AU - Dombi, Péter

AU - Tóth, Antal

AU - Borbényi, Zita

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study. HUSOM was a phase III open-label, single-arm, multi-centre study aimed to assess the efficacy and the safety of the 12 cycles of rituximab (375 mg/m2 every 8 weeks) maintenance therapy in patients had already presented partial or complete response to R-CVP or R-CHOP. Efficacy endpoints such as event-free survival and overall survival were estimated. Adverse events were recorded during the entire course of the study. A total number of 124 patients were enrolled by 15 Hungarian study sites. Out of these, 86 patients received 12 cycles of rituximab and 69 patients completed the 3-year follow-up phase as well. The probabilities of the event free survival and progression at 4.3 years were estimated to be 70.3% and 74.4%, respectively. The overall and the disease free survival at 4 years were estimated to be 90.7% and 87.9%, respectively. A total number of 85 adverse events were reported during the study out of which 5 AEs were considered to be related to the administration of rituximab. Analyses of the efficacy variables have revealed comparable results to those reported by controlled clinical trials (EORTC 20981, PRIMA) conducted in parallel with the HUSOM study.

AB - Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study. HUSOM was a phase III open-label, single-arm, multi-centre study aimed to assess the efficacy and the safety of the 12 cycles of rituximab (375 mg/m2 every 8 weeks) maintenance therapy in patients had already presented partial or complete response to R-CVP or R-CHOP. Efficacy endpoints such as event-free survival and overall survival were estimated. Adverse events were recorded during the entire course of the study. A total number of 124 patients were enrolled by 15 Hungarian study sites. Out of these, 86 patients received 12 cycles of rituximab and 69 patients completed the 3-year follow-up phase as well. The probabilities of the event free survival and progression at 4.3 years were estimated to be 70.3% and 74.4%, respectively. The overall and the disease free survival at 4 years were estimated to be 90.7% and 87.9%, respectively. A total number of 85 adverse events were reported during the study out of which 5 AEs were considered to be related to the administration of rituximab. Analyses of the efficacy variables have revealed comparable results to those reported by controlled clinical trials (EORTC 20981, PRIMA) conducted in parallel with the HUSOM study.

KW - Drug safety

KW - Event-free survival

KW - Follicular lymphoma

KW - Maintenance

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85018802183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018802183&partnerID=8YFLogxK

U2 - 10.1007/s12253-017-0234-2

DO - 10.1007/s12253-017-0234-2

M3 - Article

C2 - 28432650

AN - SCOPUS:85018802183

VL - 24

SP - 199

EP - 205

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -